Lipoprotein(a) and PCSK9 inhibition: clinical evidence2022-08-24
2020年11月18日 Relative to alirocumab, pooled analysis of phase 3 trials, i.e. placebo-controlled (with concomitant statin), ezetimibe-controlled (with concomitant statin), and ezetimibe-controlled (no concomitant statin), reported that median changes in Lp(a) were −25.6% vs. −2.5% in placebo-controlled studies and −21.4% vs. zero changes in
了解详情